Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
CONCLUSIONS: Treatment with VB-111 in combination with paclitaxel was safe and well tolerated. Favorable tumor responses and overall survival outcomes were associated with induction of an immunotherapeutic effect.
PMID: 32265057 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Minei TR, Harats D, Wall JA, Foxall ME, Penson RT Tags: Gynecol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Gene Therapy | Genetics | Ovarian Cancer | Ovaries | Science | Study